Alterity Therapeutics Limited
ATHEHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAlterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. Valued at $38.1M, ATHE is a micro-cap name in its sector. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Market Cap
$38.1M
Beta
-0.01
P/E (TTM)
—
P/E (Fwd)
-2.18
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.96
ROE
-55.0%
ROA
-34.1%
Cash
$37.3M
Total Debt
$193,465
Free CF
-$14.7M
52W Change
-54.0%
Annual Financials
Cash vs Debt
Where ATHE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ATHE finished 42.69% below its 150-day moving average ($4.24) and 39.70% below its 200-day moving average ($4.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATHE overbought or oversold?
At the October 20, 2026 close, ATHE's RSI(14) was 12.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $37.3M in cash comfortably exceeding the $193K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$14.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -55.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.01 suggests ATHE is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alterity Therapeutics Limited's trajectory.